



Health
Canada

Santé
Canada

April 27, 2026

Reference No. 2025-2565

Dr. Christy Morrissey
Department of Biology
University of Saskatchewan
112 Science Place
Saskatoon, SK
S7N 5E2

Dear Dr. Morrissey,

Re: Conclusions of the External Advisory Review Panel for the Notice of Objection for Imidacloprid and Its Associated End-Use Products

On June 26, 2025, Health Canada responded to the objections you raised regarding the re-evaluation decision for imidacloprid. In that response, Health Canada stated that objection 1 raised scientific doubt with respect to the emphasis placed by Health Canada on mesocosm studies when assessing risk to aquatic invertebrates in the environmental risk assessment. Under Section 35 of the *Pest Control Products Act* and the Review Panel Regulations, Health Canada convened a Review Panel to provide objective, science-based advice on the use of mesocosm studies in regulatory decision making. Specifically, Health Canada asked the Review Panel to confirm if the value used in Health Canada's calculation was sufficiently protective of aquatic vertebrate communities by responding to the following question:

"Is the effect metric (No Observed Effect Concentration (NOEC) of 0.16 µg time-weighted average /Litre (TWA/L), equivalent to 0.243 µg/L nominal, from the 2015 study, 'Outdoor microcosm study to the effects of IMIDACLOPRID SL 200 on the summer generation of the mayfly *Cloeon dipterum*.' sufficiently protective of aquatic invertebrate communities? If not, how would you recommend the Health Canada approach the effects metric selection from the identified mesocosm studies?"

The Review Panel consisted of three subject matter experts with expertise in pesticide regulation, mesocosm studies and environmental risk assessment. The panel reviewed Health Canada's assessment, the underlying data, as well as a range of scientific and technical literature in the public domain. After establishing that microcosm-based assessment is an acceptable methodology for the assessment, the panel concluded that the focal species used in the key microcosm study was appropriate for the purpose, and that the microcosm study was of sufficient reliability to be suitable for use in the risk assessment.

As per subsection 39(1) of the Act, after considering the recommendation of the External Advisory Review Panel, Health Canada, on behalf of the Minister, confirms the 2021 re-evaluation decision for imidacloprid, which will continue the registration of imidacloprid as outlined in RVD2021-05.

The Review Panel Report is posted in the Health Canada's Public Registry (Pesticide Product Information Database under Application Number [2025-2565](#)), along with an Information Note which is published on the HC website.

Thank you for your continued engagement.

Sincerely,



Digitally signed by Flint,
Jason
Date: 2026.04.27
15:44:13 -04'00'

Jason Flint
Chief Registrar, Pesticides Regulatory Directorate
Health Canada

encl.: E-mail attachment: Review Panel Report